<List><item><source>MED</source><extId>30463262</extId><pmcid>PMC6274919</pmcid><annotations><annotation><prefix>w an overall survival benefit (</prefix><exact>NCT01507168</exact><postfix>) [116]. </postfix><tags><tag><name>NCT01507168</name><uri>http://identifiers.org/clinicaltrials/NCT01507168</uri></tag></tags><id>http://europepmc.org/articles/PMC6274919#europepmc-75074052dc9f9e86f5136dba8c6882d6</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>e I clinical trial (</prefix><exact>NCT01628640</exact><postfix>) has been initiated</postfix><tags><tag><name>NCT01628640</name><uri>http://identifiers.org/clinicaltrials/NCT01628640</uri></tag></tags><id>http://europepmc.org/articles/PMC6274919#europepmc-aa8710ee1676c3b169f920e4760ee44c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>performed in Korea (</prefix><exact>NCT02008929</exact><postfix>), although the resu</postfix><tags><tag><name>NCT02008929</name><uri>http://identifiers.org/clinicaltrials/NCT02008929</uri></tag></tags><id>http://europepmc.org/articles/PMC6274919#europepmc-1d36c2f38a7c3f47149424f8e9d4a391</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>er trans-arterial chemoembolization (</prefix><exact>NCT02854839</exact><postfix>). </postfix><tags><tag><name>NCT02854839</name><uri>http://identifiers.org/clinicaltrials/NCT02854839</uri></tag></tags><id>http://europepmc.org/articles/PMC6274919#europepmc-c9202a561ea9af5d8c5494161e9fa89b</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>nstrated in the phase I trial (</prefix><exact>NCT01147380</exact><postfix>) [145]. </postfix><tags><tag><name>NCT01147380</name><uri>http://identifiers.org/clinicaltrials/NCT01147380</uri></tag></tags><id>http://europepmc.org/articles/PMC6274919#europepmc-5ffa62db039c9156f2c1d18ee370de0d</id><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>